Christopher Cano - Tff Pharmaceuticals COO Devel
| TFFP Stock | USD 0.30 0.02 6.25% |
Insider
Christopher Cano is COO Devel of Tff Pharmaceuticals
| Age | 53 |
| Address | 1751 River Run, Fort Worth, TX, United States, 76107 |
| Phone | 817 438 6168 |
| Web | https://tffpharma.com |
Tff Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (1.0591) % which means that it has lost $1.0591 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.1351) %, meaning that it created substantial loss on money invested by shareholders. Tff Pharmaceuticals' management efficiency ratios could be used to measure how well Tff Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of 11/27/2024, Return On Tangible Assets is likely to drop to -1.85. In addition to that, Return On Capital Employed is likely to grow to -2.17. At this time, Tff Pharmaceuticals' Total Current Liabilities is relatively stable compared to the past year. As of 11/27/2024, Liabilities And Stockholders Equity is likely to grow to about 20.7 M, while Non Current Liabilities Total is likely to drop slightly above 30.2 K.Similar Executives
| Showing other executives | INSIDER Age | ||
| Tomasz Kula | Tscan Therapeutics | N/A | |
| Pamela Garzone | Anixa Biosciences | 69 | |
| DVM MS | Lantern Pharma | N/A | |
| Andrew CPA | Cognition Therapeutics | 64 | |
| Eric Easom | AN2 Therapeutics | 56 | |
| Mark White | Annovis Bio | 68 | |
| Reid McCarthy | Annovis Bio | 66 | |
| Michael Alley | AN2 Therapeutics | N/A | |
| JD MSc | Cue Biopharma | 61 | |
| Ray Lockard | Tscan Therapeutics | N/A | |
| Michael Myers | Quoin Pharmaceuticals Ltd | 62 | |
| Claudine Bruck | Annovis Bio | 65 | |
| Sanjay Chanda | AN2 Therapeutics | 59 | |
| Kenneth LaMontagne | In8bio Inc | N/A | |
| Kenneth MD | Cue Biopharma | 64 | |
| MD FACP | AN2 Therapeutics | 76 | |
| William Ho | In8bio Inc | 45 | |
| Gordon JD | Quoin Pharmaceuticals Ltd | 60 | |
| Corleen Roche | Immunome | 57 | |
| Matthew Robinson | Immunome | N/A | |
| BSc FRCPath | INmune Bio | 59 | |
Management Performance
| Return On Equity | -2.14 | ||||
| Return On Asset | -1.06 |
Tff Pharmaceuticals Leadership Team
Elected by the shareholders, the Tff Pharmaceuticals' board of directors comprises two types of representatives: Tff Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Tff. The board's role is to monitor Tff Pharmaceuticals' management team and ensure that shareholders' interests are well served. Tff Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Tff Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Harlan Weisman, Interim Chairman | ||
| Zamaneh MD, Chief Officer | ||
| Kirk Coleman, Treasurer CFO | ||
| Paul Manley, Head Affairs | ||
| Anthony Hickey, Chief Officer | ||
| Christopher Cano, COO Devel | ||
| Dale Christensen, Head Devel | ||
| Glenn Mattes, CEO Pres |
Tff Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Tff Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -2.14 | ||||
| Return On Asset | -1.06 | ||||
| Operating Margin | (6.09) % | ||||
| Current Valuation | (1.2 M) | ||||
| Shares Outstanding | 4.44 M | ||||
| Shares Owned By Insiders | 3.31 % | ||||
| Shares Owned By Institutions | 24.37 % | ||||
| Number Of Shares Shorted | 171.96 K | ||||
| Price To Book | 0.43 X | ||||
| Price To Sales | 1.12 X |
Pair Trading with Tff Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Tff Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Tff Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving together with Tff Stock
| 0.64 | VALN | Valneva SE ADR | PairCorr |
| 0.68 | JNJ | Johnson Johnson Sell-off Trend | PairCorr |
| 0.79 | LLY | Eli Lilly Buyout Trend | PairCorr |
Moving against Tff Stock
| 0.65 | BMY | Bristol Myers Squibb Sell-off Trend | PairCorr |
| 0.55 | NAMS | NewAmsterdam Pharma | PairCorr |
| 0.34 | GILD | Gilead Sciences | PairCorr |
| 0.34 | MNOV | MediciNova | PairCorr |
The ability to find closely correlated positions to Tff Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Tff Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Tff Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Tff Pharmaceuticals to buy it.
The correlation of Tff Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Tff Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Tff Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Tff Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Tff Stock Analysis
When running Tff Pharmaceuticals' price analysis, check to measure Tff Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tff Pharmaceuticals is operating at the current time. Most of Tff Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Tff Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tff Pharmaceuticals' price. Additionally, you may evaluate how the addition of Tff Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.